Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022 the use ...

Number 5: Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...